



Diabetes UK 2025 Professional Conference

February 26-28, 2025; Glasgow, Scotland; Resource Hub – Draft

Welcome to our resource hub for Diabetes UK 2025! This is a one-stop-shop for all your Diabetes UK needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

Important Conference Information. All sessions will be held in-person at the Scottish Event Campus in Glasgow. There is no virtual registration option.

Table of Contents

[Useful Conference Links](#)

[Day-of Conference Reports](#)

[Diabetes Therapy Highlights](#)

[Diabetes Technology Highlights](#)

[Diabetes Big Picture Highlights](#)

[Previous Diabetes UK Coverage on CCKB](#)

Useful Conference Links

1. [Conference Website](#)
2. [Conference Registration](#)
3. [Day-by-Day Conference Preview](#)
4. [Conference Program](#)

Day-of Conference Reports

1. [Day #1 Highlights](#)
2. [Day #2 Highlights](#)
3. [Day #3 Highlights](#)

Diabetes Therapy Highlights

1. [The importance of T1D delay](#): Prof. Colin Dayan discusses the risks of insulin; Dr. Kimber Simmons highlights real-world insight of Tziel
2. [The importance of follow-up](#): Dr. Rachel Besser on continued monitoring of pre-stage 3 T1D
3. [Prof. Parth Narendran](#) on T1D screening efforts and follow-up strategies
4. [Current evidence, guidelines, and recommendations](#) for early detection and management of heart, liver, and kidney disease
5. [Prospective cohort study on screening](#) for MASLD and advanced fibrosis in people with T2D
6. [Prospective study \(n=718\)](#) highlights factors contributing to CKD progression over 24 years in people with T2D
7. [Type 1 Diabetes Grand Challenge Symposium Overview](#): Range of studies dedicated to research on beta cell therapy, root causes, and novel insulin
8. [T1D Grand Challenge Symposium](#): Progress in beta cell therapy takes center stage

9. [T1D Grand Challenge Symposium](#): Novel insulin innovations
10. [T1D Grand Challenge Symposium](#): Root causes under question
11. [Transformative implications](#) of stem-cell derived islets, hypoimmune cells, and autologous iPSC
12. [Drs. Kushala Abeysekera and Tessa Cacciottolo](#) on the history, epidemiology, and mechanism of MASH/MASLD
13. [The need for MASLD-specific treatments](#) and adherence to standards of care for optimal outcomes

Diabetes Technology Highlights

1. [Dr. Charlotte Boughton](#): Current management tools for T2D are insufficient; new COYOTE trial of fully closed-loop CamAPS HX in T2D initiated
2. [Prof. Partha Kar surveys England's journey](#) in expanding equitable use of CGM and AID, emphasizing the need to address unconscious biases
3. [Dr. Emma Wilmot presents additional real-world outcomes](#) among adult Omnipod 5 users in the UK (n=12,226): Median TIR of 70% at lowest target setting across all age groups
4. [Additional real-world Omnipod 5 outcomes](#) among children and adolescents with T1D in the UK (n=11,356) demonstrate low rates of hypoglycemia with strong TIR
5. [Safety and efficacy of diabetes technology](#) in emerging populations (T2D, inpatient care, and more)
6. [First National Diabetes Experience Survey \(n=42,502\)](#) in England suggests need for greater focus on exercise and emotional needs; lack of perceived need or knowledge leads as reasons for not using diabetes technology

Diabetes Big Picture Highlights

1. [Banting Memorial Lecture](#): Dr. Johnathan Valabhji discusses innovative force and dedication to the field
2. [Exhibit Hall](#): CGM, AID, GLP-1s, and more
3. [Questions about metabolic health](#): Prof. Nita Forouhi unpacks multiple controversies around carbohydrates, meat, and ultra-processed foods
4. [From prevention to management to remission](#): evidence-based success on the best diet for T2D
5. [Dangers surrounding the avoidance of seeking care](#): A survey of global majority communities
6. [Practical tips and recommendations](#) for addressing T2D in children and young adults
7. ["What we wish you knew and why"](#): The importance of peer support, education and advocacy in driving policy change
8. [The growing challenge](#): Early-onset type 2 diabetes and the socioeconomic factors at play
9. [Dorothy Hodgkin Lecture](#): Prof. Inês Barroso on translating genetic discoveries into advancements for patients

Previous Diabetes UK Coverage on CCKB

1. [Diabetes UK 2024 Full Report](#)
2. [Diabetes UK 2023 Resource Hub](#)
3. [Diabetes UK 2022 Resource Hub](#)
4. [Diabetes UK 2021 Full Report](#)
5. [Diabetes UK 2019 Full Report](#)
6. [Diabetes UK 2018 Full Report](#)
7. [Diabetes UK 2017 Full Report](#)
8. [Diabetes UK 2016 Full Report](#)